Full-Time

Scientist 1

Image Analysis/Dosimetry, Oncology

Posted on 2/21/2026

Perceptive

Perceptive

1,001-5,000 employees

Imaging core labs and eClinical solutions

Compensation Overview

$63.6k - $120.1k/yr

Remote in USA + 2 more

More locations: London, UK | Remote in France

Remote

Category
Biology & Biotech (2)
,

Get referred to Perceptive

See people who can refer or advise you

Requirements
  • PhD or MSc in a relevant field (e.g. engineering, mathematics, physics, chemistry or biology)
  • Minimum of 2 years relevant experience in medical image analysis
  • Required experience analyzing imaging data from nuclear medicine imaging modalities (e.g. PET, SPECT)
Responsibilities
  • Analyze nuclear medical imaging data, gamma counter data and associated non-image data
  • Manage data (including in DICOM format) on online project repositories
  • Oversee processing of imaging data, including registration, segmentation, ROI quantification
  • Interact with sponsors around study setup and results interpretation
  • Draft project documentation and regulatory documents
  • Ensure quality control of analysis projects
  • Analysis project management
  • Create images, plots, and reports for clients
  • Effectively utilize in-house developed python workflows, iPACS, MIM
  • Automate workflows by implementing software scripts
  • Guided internal development work

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Supported over 400 regulatory approvals across global offices.
  • Over 55 ophthalmology trials with specialized imaging endpoints.
  • 3,000+ CNS studies leveraging 15+ years neuroimaging expertise.

What critics are saying

  • EORTC extended Medidata partnership September 2024, slashing 15% EU revenue.
  • Telios Alpha-SPECT captures radiopharmaceutical market share in 6-12 months.
  • Molecular Imaging AI poaches $15M-funded clients in 3-6 months.

What makes Perceptive unique

  • Perceptive rebranded from Calyx and inviCRO merger in September 2024.
  • α-Sight™ launched with MH3D for alpha radiopharmaceutical imaging.
  • Secured $15M from CapVest to expand Astatine-211 facilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.

INACTIVE